Loading stock data…
OPRX
$5.43+0.31 (+6.05%)
After Hours$5.43+0.00 (+0.00%)· Last close Jun 29
OptimizeRx Corporation operates as a digital healthcare technology company.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OptimizeRx Corporation in the Healthcare sector is trading at $5.43 with a market capitalization of $100M. Wall Street consensus targets $12.40 (5 analysts), implying a +128.4% move over the next 12 months. The stock is currently near its 52-week low of $4.54, remaining 51.2% below its 200-day moving average. On fundamentals, Piotroski 9/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +128.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.84M↓ | $32.24M↑ | $26.07M↓ | $29.20M↑ | $21.93M |
| Gross Profit | $14.93M↓ | $24.10M↑ | $17.52M↓ | $18.64M↑ | $13.34M |
| Operating Income | $396,000↓ | $8.94M↑ | $2.05M↓ | $3.19M↑ | -$2.10M |
| Net Income | -$495,000↓ | $5.02M↑ | $779,000↓ | $1.53M↑ | -$2.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, wh...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$99.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.27%
Volume
Today's trading volume
354,653
Recent News
OptimizeRx (OPRX) Stock Sees Fair Value Cut As Analysts Reset Growth Expectations
OptimizeRx’s updated fair value estimate has been trimmed from US$14.50 to US$11.50, a reduction of about 21% that resets expectations around what the stock might be worth. Street research now clusters price targets between roughly US$7 and US$14, reflecting a split view on how quickly current initiatives can translate into revenue and support these revised levels. Read on to see what is driving these shifts in opinion and how you can track the evolving OptimizeRx story from here. Analyst...
OptimizeRx: A Good Business That Has Not Yet Earned Back Investor Trust
A promising healthcare marketing platform is priced like a bargain, but investors need cleaner numbers, stronger DAAP traction and proof that EHR partners won't capture the upside.
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.